Baricitinib
Baricitinib is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM in cell-free assays, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2. Baricitinib is found to reduce or interrupt the passage of the virus into target cells and is used in the treatment research for COVID-19. Phase 3.
| Trivial name | INCB028050, LY3009104 |
| Catalog Number | S2851 |
| Molecular Formula | C23H29FN6O |
| CAS# | 1187594-09-7 |
| Inchi | InChI=1S/C23H29FN6O/c1-13-9-18(24)19(29-22(31)26-8-7-23(3,4)5)11-16(13)17-10-15-12-27-21(25-6)30-20(15)28-14(17)2/h9-12H,7-8H2,1-6H3,(H2,26,29,31)(H,25,27,28,30) |
| Inchi Key | HHCBMISMPSAZBF-UHFFFAOYSA-N |
| SMILES | CC1=CC(=C(C=C1C2=C(N=C3C(=C2)C=NC(=N3)NC)C)NC(=O)NCCC(C)(C)C)F |
| Size | 5mg |
| Supplier Page | http://www.selleckchem.com/products/baricitinib-ly3009104.html |
| Additional Information | https://file.selleck.cn/downloads/struct/Baricitinib-chemical-structure-s2851.gif |